Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for an open-label, multicentre, randomised controlled trial

MLA

Marc Lipman, et al. “Evaluating the Effect of Short-Course Rifapentine-Based Regimens with or without Enhanced Behaviour-Targeted Treatment Support on Adherence and Completion of Treatment for Latent Tuberculosis Infection among Adults in the UK (RID-TB: Treat): Protocol for an Open-Label, Multicentre, Randomised Controlled Trial.” BMJ Open, vol. 12, no. 9, Sept. 2022. EBSCOhost, https://doi.org/10.1136/bmjopen-2021-057717.

APA

Marc Lipman, Ibrahim Abubakar, Chris Griffiths, Robert Horne, Alex Ghanouni, Heinke Kunst, Mike Mandelbaum, Molebogeng X Rangaka, Karen Sanders, Peter J White, Angela Crook, Dominik Zenner, Trinh Duong, Vanessa Hack, Julian Surey, Yohhei Hamada, Henry Bern, Joanna Calvert, Marie Francis, … Charlotte Layton. (2022). Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for an open-label, multicentre, randomised controlled trial. BMJ Open, 12(9). https://doi.org/10.1136/bmjopen-2021-057717

Chicago

Marc Lipman, Ibrahim Abubakar, Chris Griffiths, Robert Horne, Alex Ghanouni, Heinke Kunst, Mike Mandelbaum, et al. 2022. “Evaluating the Effect of Short-Course Rifapentine-Based Regimens with or without Enhanced Behaviour-Targeted Treatment Support on Adherence and Completion of Treatment for Latent Tuberculosis Infection among Adults in the UK (RID-TB: Treat): Protocol for an Open-Label, Multicentre, Randomised Controlled Trial.” BMJ Open 12 (9). doi:10.1136/bmjopen-2021-057717.